➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Colorcon
Johnson and Johnson
McKesson
Merck

Last Updated: October 20, 2021

DrugPatentWatch Database Preview

Hyaluronidase recombinant human - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for hyaluronidase recombinant human

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Abdullah KhanPhase 1
TakedaPhase 1/Phase 2
Brigham and Women's HospitalEarly Phase 1

See all hyaluronidase recombinant human clinical trials

Recent Litigation for hyaluronidase recombinant human

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19
Halozyme, Inc. v. Lee2016-12-18

See all hyaluronidase recombinant human litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hyaluronidase recombinant human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hyaluronidase recombinant human Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 2005-12-02 ⤷  Free Forever Trial Halozyme, Inc. (San Diego, CA) 2039-09-22 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 2005-12-02 ⤷  Free Forever Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 2005-12-02 ⤷  Free Forever Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
Halozyme Therap HYLENEX RECOMBINANT hyaluronidase recombinant human INJECTABLE;INJECTION 021859 2005-12-02 ⤷  Free Forever Trial Halozyme, Inc. (San Diego, CA) 2023-03-05 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for hyaluronidase recombinant human Derived from Patent Text Search

No patents found based on company disclosures

Supplementary Protection Certificates for hyaluronidase recombinant human

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
16C/036 Belgium ⤷  Free Forever Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAIN RECOMBINANT; AUTHORISATION NUMBER AND DATE: EU/1/98/067 20140326
2016000025345 Italy ⤷  Free Forever Trial PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
0822 Netherlands ⤷  Free Forever Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2016000049 Germany ⤷  Free Forever Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
2015031 Lithuania ⤷  Free Forever Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016022 Lithuania ⤷  Free Forever Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Medtronic
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.